首页> 外文期刊>Bioorganic and medicinal chemistry >Carbonic anhydrase inhibitors: Synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties
【24h】

Carbonic anhydrase inhibitors: Synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties

机译:碳酸酐酶抑制剂:用苯磺胺酰胺掺入4-硝基亚酰亚胺部分的合成和抑制人碳酸酐酶同种型I,II,IX和XII的合成和抑制

获取原文
获取原文并翻译 | 示例
           

摘要

A series of 4 and 5 nitro-1,3-dioxoisoindolin-2-yl benzenesulfonamide derivatives (compounds 1-8) was synthesized by reaction of benzenesulfonamide derivatives with 4 and 3-nitrophthalic anhydrides. These new sulfonamides were investigated as inhibitors of the zinc metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) and more specifically against the human (h) cytosolic isoforms hCA I and II and the transmembrane, tumor-associated hCA IX and XII. Most of the novel compounds were medium potency-weak hCA I inhibitors (Kis in the range of 295-10,000 nM), but were more effective hCA II inhibitors (K is of 1.7-887 nM). The tumor-associated hCA IX was also inhibited, with Kis in the micromolar range, whereas against hCA XII the inhibition constants were in the range of 90-3746 nM. The structure-activity relationship (SAR) with this series of sulfonamides is straightforward, with the main features leading to good activity for each isoforms being established. The high sequence hCA alignment homology and molecular docking studies was performed in order to rationalize the activities reported and binding mode to different hCA as inhibitors.
机译:通过用4和3-硝酸苯甲酸酐的反应,通过苯磺胺胺衍生物的反应合成了一系列4和5硝基-1,3-二氧基氨基啉-2-基苯磺酰胺衍生物(化合物1-8)。研究了这些新的磺胺酰胺作为锌金属酶碳酸酐酶(CA,EC 4.2.1.1)的抑制剂,更具体地抵抗人(H)细胞溶质同种型HC 8和II以及跨膜,肿瘤相关的HCA IX和XII。大多数新型化合物是中效弱HCA I抑制剂(kis在295-10,000nm的范围内),但更有效的HCA II抑制剂(K为1.7-887nm)。肿瘤相关的HCA IX也被抑制,KIS在微摩拉范围内,而抗HCA XII抑制常数在90-3746nm的范围内。具有这一系列磺胺酰胺的结构 - 活性关系(SAR)是简单的,主要特征导致正在建立每个同种型的良好活动。进行高序列HCA对准同源性和分子对接研究,以使报告的活性和将与抑制剂的不同HCA的结合模式合理化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号